What Researchers Did
Researchers reviewed major clinical research advances in gynecologic cancer in 2019, covering topics such as pembrolizumab for cervical cancer, PARP inhibitors for ovarian cancer, and therapies for uterine corpus cancer.
What They Found
The review identified 12 major research advances in gynecologic oncology in 2019, including significant clinical activity of pembrolizumab in advanced cervical cancer from the phase 2 KEYNOTE-158 trial. It also covered 5 topics related to ovarian cancer, such as PARP inhibitors and secondary cytoreductive surgery, alongside advances in uterine corpus cancer and radiation oncology.
What This Means for Canadian Patients
Canadian patients with gynecologic cancers may benefit from these summarized research advances, potentially leading to improved treatment options for cervical, ovarian, and uterine corpus cancers. These findings could inform clinical practice and guide future therapeutic strategies in Canada.
Canadian Relevance
This review article does not have a direct Canadian connection, as it summarizes global research advances in gynecologic oncology.
Study Limitations
As a review article, this study's findings are limited by the selection criteria and inherent limitations of the original studies it summarized.